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project brief

INTRODUCING THE PROGESTERONE
CONTRACEPTIVE VAGINAL RING
IN SUB-SAHARAN AFRICA
Research supports the introduction of the
Progesterone Vaginal Ring (PVR), a user-controlled
method that helps breastfeeding women safely
space or delay their next pregnancy.
In sub-Saharan Africa, particularly across Kenya, Nigeria, and
Senegal, ongoing efforts are helping expand access to contraceptive
methods for breastfeeding women. These efforts begin with basic
research and development to bring innovations in family planning
from bench to bedside, and continue with a deepening
understanding of the intricacies of product introduction in
underserved communities.
For the first six months after childbirth, exclusive breastfeeding
provides effective contraception, but many women do not or are
unable to breastfeed exclusively. Once a woman stops
breastfeeding, begins adding other foods or liquids to her infant’s
diet, or starts menstruating again, she is at risk of becoming
pregnant.

SEPTEMBER 2016

To bridge the gap between the demand for innovation and access to
novel contraceptive options for breastfeeding women, the
Population Council and its partners conducted three distinct
Willingness to Pay research initiatives to estimate the effect of price
on demand for the Progesterone Vaginal Ring (PVR) in sub-Saharan
Africa, where unmet need is outpacing the ability to provide timely,
cost-effective access to new methods.
Additionally, changes in the resource landscape have prompted
governments to explore “Total Market” solutions. The Total Market
Approach is defined as a coordinated approach that serves all
clients in a country—from those requiring free or highly subsidized
services to those who are willing and able to pay—to maximize
access, equity, and sustainability and to direct scarce resources to
sectors and users where need is not met. Using this as a guiding
design principle, this research provides new insights on the amount
consumers are willing to pay for the PVR from various service
sectors—public, private nonprofit, and private commercial (Evidence
Project 2014; Obare et al. 2014).

The Population Council conducts research and delivers solutions that
improve lives around the world. Big ideas supported by evidence:
It’s our model for global change. popcouncil.org
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UNDERSTANDING THE PVR:
WHAT IT IS, HOW IT WORKS
The PVR releases a continuous
low dose of the natural hormone
progesterone, which reinforces
the inhibitory effect of breastfeeding on ovulation, delays the
return of the menstrual cycle,
and therefore prevents
pregnancy without affecting the
quality of breast milk.
A woman can begin using the
PVR as early as six weeks after
birth if her menstrual cycle has
not yet returned. A single ring can
be used for three months and a
woman can replace it with a new
one up until her child’s first
birthday.
In clinical trials, the PVR was
98.5% effective in preventing
pregnancy when used correctly.

RESEARCH AND KEY FINDINGS
Within each country, the Council and partners sought to:


Evaluate the willingness to pay for the PVR
among women at health facilities in the public,
private nonprofit, and private commercial sectors.



Assess providers’ willingness across public,
private nonprofit, and private commercial sectors
to counsel and offer the PVR to women.



Understand the willingness to procure the PVR
among suppliers (e.g., governments, donors).

Stakeholders noted consistent reasons supporting the
willingness to pay, including provider recommendations of
the PVR, wanting/liking the method, desire to prevent
unintended pregnancy, and heightened interest in helping
broaden access to the PVR for women.
Overall, although cost plays an important role in
regulating consumer demand, women and their health
care providers indicated that the desire to avoid
unintended pregnancy and the need for access to modern
contraception outweighed cost barriers as critical
components that influence family planning decisionmaking. Provider interest in a woman-controlled method
that requires minimal provider counseling to ease the
burden on their time and the possibility of distribution
through community health workers was evident.
Across all three countries, most participants (up to 85% of
women, 95% of procurers, and 100% of providers)
expressed interest in the one-year Nestorone®/Ethinyl
Estradiol contraceptive vaginal ring (CVR) and even
expressed a willingness to pay higher prices for the ring.

births in urban and rural regions, respectively). And, just
more than half of married women (58%) are using a
contraceptive method, although contraceptive
prevalence reportedly increases substantially with
higher education rates. Despite the progress made in
contraceptive use, many women are still left behind—
especially those who need access to a contraceptive in
the first 12 months postpartum.
In this study, willingness to pay was evaluated in
Nairobi County, as it has the highest concentration
of urban, educated women. And, because family
planning counseling is offered free of charge, the
study sought to understand whether women,
providers, and procurers would be receptive to
paying for and obtaining the PVR, especially given
the global effort to move economies toward a Total
Market Approach.
Key findings from the Kenya WTP study (Liambila et al.
2015) include:


Women reported that they would be willing to
pay for the PVR if it was available to them.



A majority who obtain services through the
private commercial sector spend, on average,
between 50 cents and US$2 (50–199 Kenya
shillings [KES]) each month on family planning—
suggesting a market exists for the introduction
of new products via the private sector.



Most women surveyed would pay a price
equal to a three-month supply of progestinonly pills, plus a 10% increase. Women who
rely on the public sector for the provision of
family planning services were more sensitive
to marginal price increases compared with
those interviewed at private-sector facilities.



A majority noted that they would look for
affordable alternatives (52%) and go to
places where the PVR might be provided free
of charge (27%) if the selling price of the PVR
is too high for them.



Providers highlighted the value of the PVR as
an important addition to the contraceptive
method mix, particularly in light of frequent
prolonged stock-outs of other methods—
including oral contraceptives.

WILLINGNESS TO PAY: KENYA
The public sector remains the primary source of sexual
and reproductive health care financing in Kenya, but
funding shortages have prompted the exploration of new
financing models to help meet the contraceptive needs of
women and their families. So the private sector remains a
key option for contraceptive security. As Kenya is among
the most vibrant economies in East Africa (with 4.9%
economic growth reported in the first quarter of 2015),
it’s even more important to equip and empower women
with a range of family planning services and resources to
help maintain their health and support their contributions
to economic growth.
While Kenya’s total fertility rate (TFR) has declined
significantly since the mid-1970s, the current rate
remains at roughly 3.9 births per woman (3.1 and 4.5
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Interestingly, procurers expressed willingness to
make the PVR available through their networks and
indicated willingness to purchase at a higher cost
than what women reported.

Taken together, these findings indicate a high level of
interest in seeking, obtaining, and providing the PVR
across a diverse range of stakeholders in Kenya, and
underscore the value that social marketing
organizations and commercial groups can play in
helping ease the burden on public health
expenditures.
By leveraging Kenya’s growing economy and
supporting cross-collaboration through the provision
of family planning services, these findings accentuate
a positive outlook for postpartum breastfeeding
women who need access to novel, woman-controlled,
discreet methods without placing a burden on
already-stretched health care resources.

WILLINGNESS TO PAY: NIGERIA
In Nigeria, family planning financing was entirely donordriven until 2011 when the Federal Government of
Nigeria committed to providing US$3 million annually
from 2011 to 2015 for procurement of contraceptives for
the public sector. Following the London summit in 2012,
the Nigerian government made a further pledge of
providing an additional US$8.3 million.
Contraceptive services and commodities are
available free of charge at public health facilities in
Nigeria; however, public facilities have frequent
stock-outs and therefore the private sector accounts
for more than 60% of provision across rural and
urban settings.
Over the last two decades, Nigeria’s contraceptive
prevalence rate (CPR) for modern contraception has
remained steadily at 10%, representing one of the
lowest rates in sub-Saharan Africa. However,
Nigeria’s Federal Ministry of Health has set an
ambitious new target of raising the CPR to more than
35% by the year 2018. One method identified to help
achieve this goal is addressing the needs of
postpartum women, where the need is 65% (as
opposed to just above 15% for nonpostpartum
women). Further, procurement, pricing, and quality
assurance systems are particularly robust in Nigeria.
In the country, providers across all three sectors indicated
the importance of including the PVR in the method mix.
Their responses highlighted the importance of educating
potential providers to ensure their successful integration
when eventually registered.
Key findings from the Nigeria analysis (Ishaku et al.
2015) include:
•
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Women, providers, and procurers
unanimously expressed support for the PVR

suggesting that the method could represent a
welcome development and add value to the
family planning landscape.


Women were willing to pay for the PVR
regardless of the sector at a price of US$1.70
(300 Naira [N]); and, in the private
commercial and nonprofit sectors, a
significant portion of women noted
willingness to purchase the PVR at higher
prices.



Stakeholders also expressed interest and
support/willingness to try the one-year
investigational CVR—a ring that, if approved
by regulatory authorities, could potentially be
used for up to one full year.

WILLINGNESS TO PAY: SENEGAL
With a population estimated at 13 million in 2014,
Senegal continues to face a high population growth
rate (approximately 2.5%). Consequently, this
growth rate contributes to a predominantly young
population (more than 50% under 18 years of age),
which should lead to a higher fertility rate (births
per 1,000 women of reproductive age) in the next
decade. According to 2013 estimates, Senegal’s
total fertility rate is about 5.3 children per woman.
The desire for large families in Senegal comes from
cultural beliefs that children bring life into the
household and are an investment. High fertility
is also related to the low use of modern
contraception. Following its engagement in the
Ouagadougou Declaration, the Ministry of Health
launched a voluntary National Action Plan for
Family Planning in 2012. The objective is to
increase the Contraceptive Prevalence Rate from
12% to 27% by 2015 and 45% in 2020.
Senegal’s Dakar region—which boasts the highest
population density—maintains an unmet need for
family planning of 32%, which has remained
constant despite a higher modern CPR of 21%,
due in part to frequent stock-outs. According to
DHS records from 2010–11, 60% of women who
gave birth in the two years prior to the survey
reported unmet need. Among postpartum women,
66% who were breastfeeding reported unmet
need versus 40% for those not breastfeeding.

Key findings from the Senegal analysis (Mané et al.
2015) include:








Women in the public and private nonprofit
sectors were willing to pay US$1–$2 (500–
1,000 FCFA) for the PVR. And, among
potential users who learned about the PVR for
the first time, more than 70% expressed
interest in using it—and this “willingness to try”
highlights the high unmet need and
opportunity for the PVR in creating value for
Senegalese women.
Of women interested, more than 85% reported
willingness to pay, even if the price rose, to
avoid unintended pregnancy.
Across all sectors, health care providers
reported willingness to offer the PVR—and
supported its inclusion in the country’s
national family planning program. Providers
also supported a price as high as US$2 per
ring (1,000 FCFA) in the public and private
nonprofit sectors, with those in the
commercial private sector willing to pay more.
Procurers were unanimously supportive of the
PVR and recommended prices as high as
US$4.

CONCLUSIONS AND KEY LEARNINGS
Product introduction strategies demand rigorous
market research and often rely on hypothetical
approaches to gauge demand, provider interest, and
procurers’ ability and willingness to make new
contraceptive methods available to the women who
need them most. In addition to considering what price
stakeholders are willing to pay, it is essential to weigh
price against a stream of potential benefits—the
potential health outcomes, improvements and
efficiencies in the health system, and individual and
societal health and economic gains. Furthermore, a
pricing model defines the prices paid and benefits
accrued to different stakeholders.
Clinical trial results demonstrate that the PVR is safe for
both mothers and their babies, in addition to being 98.5%
effective when used correctly. Research also indicates
that women may experience other health benefits from
breastfeeding, such as reduced risk of ovarian and breast
cancer (Sivin et al. 1995; Carr et al. 2015). As such, the
PVR represents an important addition to the
contraceptive method mix and product landscape for
postpartum women in developing countries where
resources are scarce.

44

With adequate planning for the introduction of a
new contraceptive product, the health care sector
can ensure that women are able to access the
right product, in the right place, at the right time.
Sustaining an effective Total Market Approach is
key to increasing family planning access and use,
as well as ensuring continuation of services across
public and private sectors. Central to this
approach is that providers in the public and
private sectors leverage their comparative
advantages to reach different types of clients with
appropriate products and services.
The PVR contributes to a Total Market Approach
by reaching new clients who might otherwise be
overlooked due to resource constraints, creating
the opportunity to improve equitable access.
In addition to the PVR, the Population Council and
its partners are continuing development of a oneyear, long-acting, reversible contraceptive vaginal
ring (CVR) containing two hormones that, if
approved by regulatory agencies, could be used
by nonbreastfeeding women. In each study,
participants were asked if they would be
interested in this method as an alternative to
other long-acting methods (e.g., IUDs), because
the CVR is also designed to be woman-controlled
and would offer a comparable level of discretion.
Women across all three countries expressed
interest and willingness to pay for this product.
Willingness to pay and the price paid by different
stakeholders are important considerations in
the initial stages of introduction of a new
contraceptive. As the market matures for the
contraceptive, the potential for price reductions
emerges. Efficiencies in manufacturing and
distribution to meet increased demand can lower
prices, as can the entry of new manufacturers.
With the overall contraceptive market poised to
grow in the next two decades to meet the needs of
a growing population, the dynamics of supply and
demand will significantly alter the initial price
offering.
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